Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.92 USD | +0.42% | +3.91% | +203.17% |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call | |
May. 13 | Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 | MT |
Chart calendar Jasper Therapeutics, Inc.
Upcoming events on Jasper Therapeutics, Inc.
Past events on Jasper Therapeutics, Inc.
2024-05-20 08:00 am | Investor Meeting - Key Opinion Leader |
2024-05-15 03:35 pm | RBC Capital Markets Global Healthcare Conference - Fireside Chat |
2024-05-14 02:45 pm | Capital One Securities Biotech Biopharma Disruptors Conference - Panel |
2024-05-14 08:00 am | Q1 2024 Earnings Release |
2024-04-08 11:00 am | Needham Healthcare Conference |
2024-03-28 10:00 am | H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference |
2024-03-04 10:30 am | TD Cowen Health Care Conference |
2024-03-04 07:30 am | Q4 2023 Earnings Release |
2024-02-25 04:45 pm | American Academy of Allergy, Asthma & Immunology Meeting |
2024-02-24 02:00 pm | American Academy of Allergy, Asthma & Immunology Meeting |
2024-02-23 03:15 pm | American Academy of Allergy, Asthma & Immunology Meeting |
2024-02-13 04:40 pm | Oppenheimer Healthcare Life Sciences Conference |
2023-12-15 01:00 pm | Extraordinary Shareholders Meeting |
2023-12-10 12:30 pm | American Society of Hematology Meeting |
2023-11-30 02:00 pm | Piper Sandler Healthcare Conference |
2023-11-29 09:10 am | Evercore ISI HealthCONx Conference |
2023-11-15 01:50 pm | Stifel Healthcare Conference |
2023-11-10 06:45 pm | American College of Allergy Asthma & Immunology Scientific Meeting - Abstract No - 8266 |
2023-11-09 08:00 am | Q3 2023 Earnings Release |
2023-10-11 08:00 am | Investor Meeting - Key Opinion Leader |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -36,5 -35,8 -1.75% | -46,1 -48,7 5.26% | 0,00 0,00 - | 0,00 |
EBIT Million USD | Released Forecast Spread | 0,00 | -36,8 -35,4 -4.16% | -51,2 -51,3 0.28% | -68,9 -70,4 2.24% | -70,8 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -30,6 -34,8 11.89% | -37,7 -38,4 1.93% | -64,5 -66,2 2.59% | -65,3 |
Net income Million USD | Released Forecast Spread | -31,7 | -30,6 -34,8 11.89% | -37,7 -38,4 1.93% | -64,5 -66,2 2.59% | -65,3 |
EPS USD | Released Forecast Spread | -51,7 | -26,9 -22,3 -20.63% | -10,3 -10,5 1.9% | -6,18 -6,34 2.45% | -4,54 |
Announcement Date | 08/06/21 | 18/03/22 | 08/03/23 | 04/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
EBITDA Million USD | Released Forecast Spread | -12,4 -11,0 -13.09% | -11,9 -12,1 1.9% | -17,6 -12,6 -39.3% | |||||||||||
EBIT Million USD | Released Forecast Spread | -12,8 -12,1 -5.36% | -12,0 -13,9 13.95% | -12,7 -14,0 9.01% | -13,7 -13,9 0.95% | -13,9 -13,6 -2.85% | -17,8 -16,2 -9.79% | -19,4 -17,7 -9.1% | -17,7 -19,3 8.38% | -15,1 -18,4 18.13% | -17,6 | -18,6 | -19,5 | -16,1 | -16,8 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -2,21 -13,1 83.1% | -10,4 -11,6 10.66% | -11,9 -12,8 7.01% | -13,2 -13,6 2.51% | -14,3 -14,0 -1.99% | -16,1 -15,8 -1.93% | -17,5 -17,1 -2.51% | -16,6 -18,6 11.09% | -13,7 -17,4 21.26% | -16,2 | -17,1 | -18,1 | -16,1 | -16,8 |
Net income Million USD | Released Forecast Spread | -2,21 -13,1 83.1% | -10,4 -11,6 10.66% | -11,9 -12,8 7.01% | -13,2 -13,6 2.51% | -14,3 -14,0 -1.99% | -16,1 -15,8 -1.93% | -17,5 -17,1 -2.51% | -16,6 -18,6 11.09% | -13,7 -17,4 21.26% | -16,2 | -17,1 | -18,1 | -16,1 | -16,8 |
EPS USD | Released Forecast Spread | -0,60 -3,50 82.86% | -2,90 -3,13 7.45% | -3,20 -3,40 5.88% | -3,60 -3,74 3.74% | -1,60 -1,62 1.23% | -1,50 -1,50 0% | -1,60 -1,57 -2.13% | -1,50 -1,70 11.5% | -1,03 -1,23 16.4% | -1,09 | -1,16 | -1,19 | -0,83 | -0,86 |
Announcement Date | 12/05/22 | 12/08/22 | 10/11/22 | 08/03/23 | 12/05/23 | 11/08/23 | 09/11/23 | 04/03/24 | 14/05/24 | - | - | - | - | - |
2024-05-27 | DOTTIKON ES HOLDING AG: Q4 2024 Earnings Release |
2024-05-28 | IPCA LABORATORIES LIMITED: Q4 2024 Earnings Release |
2024-05-28 | FDC LIMITED: Q4 2024 Earnings Release |
2024-05-28 | ALKEM LABORATORIES LIMITED: Q4 2024 Earnings Release |
2024-05-28 | PFIZER LIMITED: Q4 2024 Earnings Release |
2024-05-29 | ASTRAZENECA PHARMA INDIA LIMITED: Q4 2024 Earnings Release |
2024-05-29 | MARKSANS PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-29 | SUVEN PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-30 07:00 am | ROIVANT SCIENCES LTD.: Q4 2023 Earnings Release |
2024-05-30 | JUBILANT PHARMOVA LIMITED: Q4 2024 Earnings Release (Projected) |
Past sector events for Jasper Therapeutics, Inc.
Today | CSPC PHARMACEUTICAL GROUP LTD.: Q1 2024 Earnings Release |
Today | NATCO PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-24 | BLUE JET HEALTHCARE LIMITED: Q4 2024 Earnings Release |
2024-05-24 | AUROBINDO PHARMA: Q4 2024 Earnings Release |
2024-05-24 | DIVI'S LABORATORIES LIMITED: Q4 2024 Earnings Release |
2024-05-24 10:56 am | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED: Q4 2024 Earnings Release |
2024-05-24 08:18 am | TORRENT PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-23 10:47 am | ORCHID PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-23 06:45 am | SHILPA MEDICARE LIMITED: Q4 2024 Earnings Release |
2024-05-22 08:06 am | GLAND PHARMA LIMITED: Q4 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- JSPR Stock
- Calendar Jasper Therapeutics, Inc.